이학박사 (미국) 아르베드 부리히터

상세 프로필

아르베드 부리히터 박사는 본과 로스앤젤레스에서 화학을 공부했다. 1997년 그는 탄화수소 화학의 영역 "오늄 이온의 양성자 활성화"(“protolytic activation of onium ions”)로, LA의 남부 캘리포니아 대학교의 노벨상 수상자인 조지 아 올라 (George A. Olah) 밑에서 박사학위를 받았다.

아르베드 부리히터는 COHAUSZ & FLORACK, 뒤셀도르프 고등 법원, 그리고 뮌헨 특허청에서 지적 재산권 법과 민법에 관한 연수를 받았다. 그는 2000년도에 독일 변리사로, 2002년도에는 유럽 변리사 자격을 얻었다. 그는 변리사 교육을 완료한 후, 미국 특허 및 상표법에 대한 경험을 쌓기 위해 몇개월 동안 뉴욕 법률 사무소에서 일했다.

부리히터 박사는 2000년도에 COHAUSZ & FLORACK에 입사했다. 그는 지적 재산권과 관련된 모든 분야에서 독일 및 국제적인 고객을 대표한다. 그의 일은 화학 및 생명과학, 제약화학, 고분자화학, 생화학 분야의 특허 및 라이센스에 초점을 맞추고 있다. 그는 또한 디자인과 실용 신안의 보호와 상표 포트폴리오의 관리를 전문으로 한다.

부리히터 박사는 독어, 영어 그리고 불어를 구사한다.

Recommendations

• Legal 500 EMEA 2022
• Chambers Europe 2022
• Chambers Global 2022
  "He is a very capable team leader and he competently takes on this role."
• Legal 500 Deutschland 2022
• IAM Global Leaders 2022
• JUVE Patent Ranking 2021/2022
  "highly experienced and knowledgeable. You always feel like you’re in the very best hands” (competitor)
• IAM Patent 1000 2021
  "Dr Burrichter’s capacity for advocating and devising effective winning strategies makes him one of the most sought-after chemistry patent counsel in Germany. He has been consistently recognised in JUVE’s patent category as one of Germany’s most frequently recommended patent attorneys for chemistry-relatedmatters."
• Leaders League 2021
  Excellent in patent prosecution
• Best Lawyers 2022
• The LEGAL 500 EMEA 2021
• Chambers Europe 2021
  “One client states: ‘He has excellent technical skills and is very easy to work with.’”
• Chambers Global 2021
  “Besides his litigation and EPO opposition work, Arwed maintains an extensive patent prosecution docket for his clients. His extensive international experience makes Arwed a sought after advisor for important strategic decisions in European patent prosecution and litigation matters.”
• The LEGAL 500 Germany 2021
• JUVE Handbuch 2020/2021
  Leading advisor among patent attorneys ("a technical authority in the market", competitor)
• IAM Patent 1000 2020
  “Arwed Burrichter has cultivated a sterling reputation among leading international chemistry and life sciences entities as a complex problem-solver. He employs an interdisciplinary scheme of thinking tanks to years of experience in patent litigation, nullity and opposition proceedings and intangible asset management."
• IAM Global Leaders 2020
• Best Lawyers 2020
• The LEGAL 500 EMEA 2020
• Chambers Global 2020
• The LEGAL 500 Deutschland 2020
• IAM Global Leaders 2020
• JUVE Handbuch 2019/2020
  Führender Name unter Patentanwälten
• Wirtschaftswoche Ranking Patenanwälte 2019
• IAM Patent 1000, 2019
  (... )“among the best for chemicals in Germany”, “a strategic thinker with the ability to thoroughly immerse himself in the technical details” (...)
• Best Lawyers 2020
• Chambers Europe und Chambers Global 2019
  Leaders in their Field
• JUVE Handbuch 2018/2019
  Führender Name unter Patentanwälten
• Chambers Europe und Chambers Global 2018
  Leaders in their Field
• The LEGAL 500 Deutschland 2018
• Wirtschaftswoche Top Anwälte, 2018
• Expert Guides 2018
• IAM Patent 1000, 2018
  "(...) On the non-contentious side of the practice, Arwed A Burrichter is a diligent portfolio builder who files with finesse and treats every patron as if they were his only one. (...)"
• Best Lawyers 2018
• Wirtschaftswoche 2018
• IAM Patent 1000, 2017
  "(...) has notable expertise in supplementary protection certificate (SPC) issues. With five years of scientific and professional experience in the United States – including a stint at what at the time was one of New York’s leading boutiques – he has a complete command of the country’s legal system."
• JUVE Handbuch 2017/2018 
  Führender Name unter Patentanwälten
• The LEGAL 500 2017
• JUVE Handbuch 2016/2017
  Führender Name unter Patentanwälten
• IAM Patent 1000, 2016
  "(...) he has a flair for pan-European portfolio management. (...)"
• The LEGAL 500 2016
• JUVE Handbuch 2015/2016 
  Führender Name unter Patentanwälten
• IAM Patent 1000, 2015
  "(...) does a sterling job for clients in the life sciences and pharmaceutical industries. (...)"